EHA 2024 | The addition of blinatumomab to prephase and consolidation therapy in adult B-ALL
Anita Rijneveld, MD, Erasmus MC, Rotterdam, Netherlands, discusses the addition of blinatumomab to prephase and consolidation therapy in adult B-cell acute lymphoblastic leukemia (B-ALL). The study showed high complete remission (CR) rates, including substantial measurable residual disease (MRD) negativity. The approach proved safe, with minimal high-grade cytokine release syndrome (CRS) and neurological toxicities. After a 43-month follow-up, overall survival (OS) was 86% in patients under 40 years old and 50% in those over. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
